Nucala (mepolizumab) — Point32Health

Initial criteria

• Documented diagnosis of hypereosinophilic syndrome
• Documentation that non-hematologic secondary causes (e.g., parasitic, allergic) have been ruled out
• Documentation of a blood eosinophil count of at least 1000 cells/mcL prior to the start of treatment
• Patient age ≥ 12 years
• Prescribed by or in consultation with an allergist, immunologist, pulmonologist, dermatologist, or gastroenterologist
• Documentation of one of the following: trial and failure with at least one of the following: an oral corticosteroid, oral immunosuppressant, or cytotoxic therapeutic agent OR contraindication to all of the following: oral corticosteroids, oral immunosuppressants, and cytotoxic therapies